ZTS Stock Zoetis Inc.
US · NYSELast in our picks 2026-10-22 — not in the current list; analysis below is from that screen
Animal-health leadership and recurring diagnostics revenue offer defensive, secular growth.
Future value: $94.43 (+18.60%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Durable demand and pipeline catalysts, but valuation requires a better entry.
- ▸Above 50-day MA (+7.14%)
- ▾Near 52-week low (13.6% of range)
Is ZTS a buy right now?
Trend: ZTS is trading above the 50-day average (+8.63%), RSI 44 — neutral momentum, with a 3-month return of +5.34%.
Valuation & quality: Zoetis Inc. trades on a trailing P/E of 13.3, forward P/E 12.6, PEG 15.08, price-to-book 10.65; fundamentals show net margin 27.7%, return on equity 64.9%, revenue growth -0.2% year on year.
Analyst consensus: 14 analysts have a mean 12-month price target of $93.00 (+14.9% vs the last close; range $74.00 – $155.00), consensus rating “buy”.
Income: trailing dividend yield 2.62%.
Our screen: ACCUMULATE (score 1) — Animal-health leadership and recurring diagnostics revenue offer defensive, secular growth.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -9.80% | -2.70% | -32.40% | -7.50% | +7.60% | -0.20% | -9.40% | +16.00% |
Fundamentals
Analyst price target
Technical signals
About Zoetis Inc.
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.
Sector: Healthcare · Industry: Drug Manufacturers - Specialty & Generic · United States · 14,500 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.